HYPD vs. KYTX, LFCR, NGNE, IMMP, FENC, DBVT, VYGR, JMAC, LYEL, and AVTE
Should you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include Kyverna Therapeutics (KYTX), Lifecore Biomedical (LFCR), Neurogene (NGNE), Prima BioMed (IMMP), Adherex Technologies (FENC), DBV Technologies (DBVT), Voyager Therapeutics (VYGR), Maxpro Capital Acquisition (JMAC), Lyell Immunopharma (LYEL), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.
Hyperion DeFi vs. Its Competitors
Kyverna Therapeutics (NASDAQ:KYTX) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
In the previous week, Hyperion DeFi had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Hyperion DeFi and 1 mentions for Kyverna Therapeutics. Hyperion DeFi's average media sentiment score of 0.67 beat Kyverna Therapeutics' score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the news media.
Kyverna Therapeutics currently has a consensus price target of $16.60, suggesting a potential upside of 200.72%. Hyperion DeFi has a consensus price target of $2.00, suggesting a potential downside of 81.93%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Hyperion DeFi.
Hyperion DeFi has lower revenue, but higher earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 22.0% of Kyverna Therapeutics shares are owned by insiders. Comparatively, 10.9% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Kyverna Therapeutics has a beta of 3.72, meaning that its share price is 272% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.
Kyverna Therapeutics has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. Kyverna Therapeutics' return on equity of -64.98% beat Hyperion DeFi's return on equity.
Summary
Kyverna Therapeutics beats Hyperion DeFi on 11 of the 17 factors compared between the two stocks.
Get Hyperion DeFi News Delivered to You Automatically
Sign up to receive the latest news and ratings for HYPD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hyperion DeFi Competitors List
Related Companies and Tools
This page (NASDAQ:HYPD) was last updated on 10/3/2025 by MarketBeat.com Staff
